Application of imaging-derived parameters to dosimetry of intravascular brachytherapy sources: perturbation effects of residual plaque burden.
The dosimetric effect of geometric and material heterogeneities on intravascular brachytherapy dose delivery has been studied recently. Residual plaque within the coronary vessel appears to have an impact on the uniform delivery of radiation dose to the arterial tissue. In this study, we have examined the effect of residual plaque burden and post-PCI (percutaneous coronary intervention) plaque configuration on the dose to the arterial wall from clinical intravascular brachytherapy beta-emitting sources containing 32P and 90Sr/90Y. Monte Carlo simulations using the MCNP4B code were performed for these catheter-based sources with residual plaque burden ranging between 25% and 50%. The residual plaque burden values were derived from post-PCI data provided in several recent clinical studies. Dose calculations were performed for three different values of plaque density (1.45 g cm(-3), 2.20 g cm(-3), and 3.1 g cm(-3)) and three different plaque morphologies for the same residual plaque burden. The dose perturbation factor (DPF), defined as the ratio of dose at 2 mm radial distance for a given case to the dose at the same radial distance in homogeneous water medium, was determined for each of the three different plaque densities. The range of DPF values was 0.81-1.01, 0.62-0.99, and 0.41-0.97 for different plaque densities for the 32P source. Corresponding DPF values for the 90Sr/90Y source were 0.90-1.01, 0.84-1.01, and 0.62-1.01. The results indicate the need for accurate assessment of post-PCI clinical measurements such as minimal lumen diameter and residual plaque burden and incorporation of these values into dose calculations.
Sehgal
Varun
V
Department of Radiation Oncology, University of Florida, Gainesville 32610-0385, USA.
Li
Zuofeng
Z
Palta
Jatinder R
JR
Smith
Karen M
KM
Bolch
W E
WE
D001918:Brachytherapy / Q000379:methods*; D006801:Humans; D007091:Image Processing, Computer-Assisted; D008962:Models, Theoretical; D009010:Monte Carlo Method; D010761:Phosphorus Radioisotopes / Q000627:therapeutic use; D011874:Radiometry / Q000379:methods; D013326:Strontium Radioisotopes / Q000627:therapeutic use; D015021:Yttrium Radioisotopes / Q000627:therapeutic use
D010761:Phosphorus Radioisotopes; D013326:Strontium Radioisotopes; D015021:Yttrium Radioisotopes